Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iX BiopharmaSGX:42C +0.92%36 Gross Margin % is 38.14% as of Mar. 2026, which is 74% above its 10-year median of 21.93. GuruFocus rates SGX:42C with a GF Score™ of 36/100 and a GF Value™ of S$0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 942 Drug Manufacturers companies, iX Biopharma ranks worse than 74.73% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
iX Biopharma had a gross margin of 38.14% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
iX Biopharma Gross Margin % Related Terms
iX Biopharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for iX Biopharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:42C vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iX Biopharma Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where iX Biopharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
iX Biopharma (SGX:42C) has a Gross Margin % of 38.14% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on iX Biopharma and its competitors. This is 74% above median its historical median of 21.93. According to the industry distribution chart, iX Biopharma ranks #704 out of 942 companies in the Drug Manufacturers industry, placing it in the top 74.7%.
Is iX Biopharma's Gross Margin % too high?
iX Biopharma's current Gross Margin % of 38.14% is 74% above median its 10-year median of 21.93. The Drug Manufacturers industry median Gross Margin % is 48.50. iX Biopharma's value of 38.14% is 21.4% below this industry median. Based on the distribution chart, iX Biopharma ranks #704 out of 942 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, iX Biopharma has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, iX Biopharma ranks #704 out of 942 companies for Gross Margin %. This places iX Biopharma in the lower half of its industry. The industry median Gross Margin % is 48.50. iX Biopharma's value of 38.14% is 21.4% below this benchmark. While the company's 10-year median is 21.93 vs. the industry median of 48.50, iX Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iX Biopharma's current Gross Margin % of 38.14% is 21.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on iX Biopharma and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iX Biopharma's current Gross Margin % is 38.14%, which is 74% above median its own 10-year median of 21.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
Based on GuruFocus' analysis, iX Biopharma (SGX:42C) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.03, compared to a current price of S$0.55 — trading 1733.3% above its estimated fair value. The current Gross Margin % is 38.14%, which is 74% above median its 10-year median of 21.93 and 21.4% below the Drug Manufacturers industry median of 48.50. iX Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current Gross Margin % is 38.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iX Biopharma (SGX:42C) Overvalued in 2026?
Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued.
The current stock price of S$0.55 is trading 1733.3% above its estimated GF Value™ of S$0.03.
GuruFocus considers iX Biopharma to be Significantly Overvalued.
Key valuation signals for SGX:42C:
Gross Margin %: 38.14% (74% above median its 10-year median of 21.93)
GF Value™: S$0.03 vs. price of S$0.55 (1733.3% above fair value)
Industry Position: 21.4% below the Drug Manufacturers median (#704 of 942)
No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score
Get the complete analysis for SGX:42C
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:42C has been successfully added to your 
